ORIGINAL ARTICLE



Unraveling the molecular interactions between α7 nicotinic receptor and a RIC3 variant associated with backward speech

Aditi Pradhan¹ · Hayley Mounford¹ · Jessica Peixinho¹ · Edward Rea^{1,2} · Emmanouela Epeslidou³ · Julia S. Scott³ · Joanna Cull¹ · Susan Maxwell⁴ · Richard Webster⁴ · David Beeson⁴ · Yin Yao Dong⁵ · Stefan Prekovic³ · Isabel Bermudez¹ · Dianne F. Newbury¹

Received: 10 July 2023 / Revised: 28 January 2024 / Accepted: 30 January 2024 © The Author(s) 2024

Abstract

Recent work putatively linked a rare genetic variant of the chaperone Resistant to Inhibitors of acetylcholinesterase (*RIC3*) (NM_024557.4:c.262G > A, NP_078833.3:p.G88R) to a unique ability to speak backwards, a language skill that is associated with exceptional working memory capacity. RIC3 is important for the folding, maturation, and functional expression of α 7 nicotinic acetylcholine receptors (nAChR). We compared and contrasted the effects of RIC3G88R on assembly, cell surface expression, and function of human α 7 receptors using fluorescent protein tagged α 7 nAChR and Förster resonance energy transfer (FRET) microscopy imaging in combination with functional assays and ¹²⁵I- α -bungarotoxin binding. As expected, the wild-type RIC3 protein was found to increase both cell surface and functional expression of α 7 receptors. In contrast, the variant form of RIC3 decreased both. FRET analysis showed that RICG88R increased the interactions between RIC3 and α 7 protein in the endoplasmic reticulum. These results provide interesting and novel data to show that a RIC3 variant alters the interaction of RIC3 and α 7, which translates to decreased cell surface and functional expression of α 7 nAChR.

Keywords RIC3 · Nicotinic acetylcholine receptors · Backward speech

Abbreviations

apFRET	Acceptor photobleaching fluorescence
	resonance energy transfer
eGFP	Enhanced green fluorescent protein
ER	Endoplasmic reticulum
FRET	Förster resonance energy transfer
nAChR	Nicotinic acetylcholine receptor

Dianne F. Newbury diannenewbury@brookes.ac.uk

- ¹ Department of Biological and Molecular Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford OX3 0BP, England
- ² Oxford Brookes Centre for Bioimaging, Oxford Brookes University, Oxford OX3 0BP, England
- ³ Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
- ⁴ Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, England
- ⁵ Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DS, England

Published	online:	12 March 2024	

MCS	Multiple cloning site
mCherry	Monomeric cherry fluorescent protein

Introduction

The homomeric α 7 nicotinic acetylcholine receptor (nAChR) is one of the most abundant nAChRs in the brain. It is highly expressed in the hippocampus, thalamus, and cortex and contributes to cognition, attention, and working memory [1-3]. Our understanding of the exact links between α 7 nAChR and cognitive functions are limited but validated links exist between a7 nAChRs and cognitive deficits associated with schizophrenia [3-5] and with Alzheimer's disease, in which α 7 is proposed to exert a neuroprotective effect [6, 7]. Furthermore, single nucleotide polymorphisms (SNPs) in the CHRNA7 gene (which encodes the α 7 subunit) have been associated with dementia [8], Alzheimer's disease [9, 10] and schizophrenia [11]. Although α 7 usually forms homopentamers, in basal forebrain neurones, it can also assemble with $\beta 2$ nAChR subunits to form heteromeric $\alpha7\beta2$ nAChRs, thus increasing its functional range [12]. The diversity of α 7 signaling is further enhanced by the ability of α 7 nAChR to link with G-proteins, diverse intracellular signal pathways, and modulate intracellular calcium release from the endoplasmic reticulum (ER) [13].

To exert its signaling functions, α 7 nAChR must be present on the cell surface, which largely depends on the correct folding and assembly of the receptor subunits in the ER and subsequent trafficking of the assembled receptor to the cell surface [14]. Robust experimental evidence indicates that the ER-resident chaperone RIC3 enhances α 7 subunit folding and oligomerization in the ER leading to "mature" assemblies that are then trafficked to the cell surface [15–18]. In host cells that do not express RIC3, heterologous expression of the chaperone cDNA enables functional expression of α7 nAChR [15, 19, 20]. RIC3 also interacts with other nAChRs and the closely related 5-HT3 serotonin receptor but its effects, which can be positive or negative, depend on the identity of the receptor subunits, the host cell [16, 19] and the ratio of receptor to RIC3 [21, 22]. Although the role of RIC3 on the expression of α 7 nAChR in vivo is not fully understood [23], RIC3 expression has been linked to cognitive maintenance [24] and, crucially, there is a good correspondence between *RIC3* and α 7 nAChR expression in the rat hippocampus [25]. Furthermore, recent autoradiographic analysis of the brain of a Ric3 knockout mouse show a decrease in 125 I- α -bungarotoxin binding in the hippocampus and the cortex [23], brain regions that contribute to working memory and language. In addition, the expression of RIC3 shows a high level of correlation with α7 nAChR in postmortem brain tissues from population and disease cohorts [26].

Our interest in RIC3 stems from its potential role in language. Several studies have linked copy number changes of chromosome 15q13.3 (the location of the CHRNA7 gene) with an increased risk of speech and language disorders, usually alongside more global developmental delays and neuropsychiatric phenotypes [27-31]. Although these chromosome rearrangements typically include 1.5-2 Mb of DNA and seven genes, smaller deletions affecting only CHRNA7 result in similar developmental profiles, leading some to suggest that haploinsufficiency of CHRNA7 underlies some of the features seen in this syndrome [32–34]. RIC3 expression is specifically upregulated in both patients with schizophrenia and bipolar disorder [26], both of which include language dysfunction [35–37]. Furthermore, a recent study investigated a case family with the unique ability to speak backwards, a language skill that they postulated was made possible by exceptional working memory capacity [38]. This study identified three potential contributory variants including a rare polymorphism in RIC3 which confers a coding change (NM_024557.4:c.262G > A, NP_078833.3:p.G88R) [38]. The genetic and behavioral bases for this skill remain unknown but the putative implication of RIC3 provides an intriguing link that we aim to substantiate on a functional level in this paper.

Given that cell surface expression is a pre-requisite for α 7 nAChR signaling, the identification of the structural domains involved in the chaperone activities of RIC3 has been a long-standing research goal. RIC3 is a disordered protein with little homology between species [17]. Its structural domains comprise an N-terminal region that contains two hydrophobic segments linked by a prolinerich linker and a long C-terminal region that contains either one (human, mouse, Drosophila) or two (C. elegans) coiled-coil motif [19] (Fig. 1). The G88R variant identified in the backward speech study occurs within a poly-glycine stretch found inside the proline-rich linker domain (Fig. 1). For invertebrate species, the two hydrophobic segments are predicted to be transmembrane domains. In contrast, for mammalian species, the location of the segments is controversial. Wang et al. working with mouse RIC3 identified a cleavable signal peptide in the N-terminus, which led to the suggestion that RIC3 is a single-pass type I transmembrane protein with its N-terminus located in the lumen of the ER and the C-terminus with its coiledcoil domain in the cytoplasm [17]. In the human RIC3, Cheng et al. [39] reported a cleavable sequence in the N-terminus of human RIC3 [39], but others found no evidence the N-terminus is cleaved during translation [25, 40]. Our findings suggest that human RIC3 is a type II transmembrane protein with the N- and C-termini facing the cytoplasm (Fig. 1). The latter topology is consistent with the findings that the complete N-terminus is crucial for efficient cell surface expression of invertebrate and mammalian α7 nAChR [17, 18, 22, 25, 40].

The exact mechanism by which RIC3 promotes α7 nAChR assembly is unknown [41] although a direct interaction is expected as α 7 co-precipitates with RIC3 [20, 42]. Wang et al. suggested that each RIC3 protein associates with a single folded α 7 subunit [17]. The receptor is then built through RIC3 dimerization at the C-terminal coiledcoil motif, pulling subunits together to form the pentamer [17]. However, others note that the coiled-coil domain is not required for RIC3 function [40, 43] and that some isoforms of RIC3 lack the coiled-coil domain but are still able to promote α 7 assembly [18, 22]. Ben-David et al. further showed that the shorter isoform, which lacks the coiled-coil domain, has different functional properties from the full protein and acts as an inhibitor of AChR assembly and function [22]. Kweon et al. later suggested that the α 7 assembly process involves a host of chaperone proteins, including NACHO, OST, RPN1/2, and calnexin, as well as RIC3 passing α 7 through the secretory pathway [44]. Each of these chaperones is thought to bind a distinct region of α 7 [44] and it has been proposed that RIC3 binds between the M3 and M4 transmembrane domains [44]. This loop is




Fig. 1 Schematic showing proposed topology and tagging of α 7 and RIC3. **A**: Two transmembrane (TM) domains result in cytoplasmic C- and N-termini. **B**: A single transmembrane domain results in a cytoplasmic C-terminal domain and a lumenal N-terminal domain.

largely disorganized but includes an MX helix and an MA helix, that runs into the M4 transmembrane domain [41]. Although studies have shown that this region is necessary for the effects of RIC3 [44] and that substitution of residues in the MA helix ablates RIC3 enhancement of assembly [25], structural modeling suggests that interactions in this region would block pentameric assembly [41].

In the present study, we examined the consequences of G88R variant on interactions between RIC3 and α 7 nAChR subunits in HEK293 mammalian cells, using RIC3 and α 7 nAChR tagged with fluorescent proteins. Led by previous research, we examined three levels of function; the cellular localization of the RIC3, interactions between RIC3 and α 7, and the surface expression of mature α 7 receptors. Using acceptor photobleaching (ap) FRET, we found that G88R increases interaction between RIC3 and α 7 in the ER. Interestingly, we found that the enhanced interaction results in decreased functional expression of α 7 nAChR in *Xenopus* oocytes and reduced 125 I- α -bungarotoxin binding in HEK293 cells. We suggest that the G to R variant exerts a functional effect through increased interaction between α 7 nAChR and RIC3 in the ER, ultimately leading to reduced functional expression.

This investigation not only establishes a functional effect for the G88R variant but provides additional evidence on the Red star denotes tagging of α 7 subunit between the TM3 and TM4 domains. Green stars represent tagging of RIC3, Pink dot denotes position of G88R variant. CC denotes coiled-coil domain

structure of RIC3 and the mechanism of interaction between RIC3 and α 7.

Methods

Reagents

¹²⁵I-α-Bungarotoxin (NEX126H050UC) was obtained from PerkinElmer, UK. Fugene was obtained from Promega (E5911). Acetylcholine (A2661), polyethylenimine, 25,000 MW (4008727), and Triton (648466) were obtained from Merck.

Cell culture and cell transfections

Human Embryonic Kidney 293 cells (HEK293, supplied by ATCC, UK) were cultured in DMEM (1X) with high glucose (Life Technologies, UK) supplemented with 10% fetal calf serum (FCS; Life Technologies, UK). Cells were used for experimentation once they reached 60–70% confluency. Cells were plated on poly-d-lysine (0.1 mg/ml, Sigma)-coated glass-bottomed μ -dish 35 mm Ibidi dishes (Thistle Scientific), UK at a density of 120,000 cells/ml. All cultures were maintained at 37 °C and 5% CO₂.

For confocal microscopy, HEK293 cells were transfected (0.5 μ g of α 7, RIC3, LCK, and ER3 plasmids) using FuGene HD (Promega) following manufacturer's instructions.

Constructs

α7 clone

Wild-type human α 7 nAChR subunits were synthesized by GeneArt (ThermoFisher, UK). The sequence of the cDNA was optimized for expression in mammalian cells. Fluorescently tagged α 7 nAChR subunits were produced by inserting mCherry cDNA into the M3-M4 cytoplasmic loop of α 7 at amino acid 391 (α 7-mCherry).The positioning of the tag has previously been demonstrated to retain the functional properties of the receptor [45] and sits 74 amino acids away from the MX helix, which is proposed to be the site of interaction between RIC3 and α 7 [46, 47]. Both wild-type and fluorescent α 7 nAChR subunit cDNAs were subcloned into the pCI expression vector (Promega, UK).

RIC3 clones

Wild-type RIC3, henceforward termed RIC3WT, cDNA (NM_024557) was amplified using primers containing EcoRI (5' TATTCGAATTCGCGTACTCCACAGTGC AGAGAGTCGCTCTGG 3') and KpnI (5' AATAAGGTA CCTCACTCTAAACCCTGGGGGGTTACGCTTCCTCAG 3') restriction sites. Site-directed mutagenesis (F-primer 5' AGGTGGAGGTGCTGGACGTGGAGGTAGTGGAAG AGG 3', R-primer 5' CCTCTTCCACTACCTCCACGT CCAGCACCTCCACCT 3') was used to introduce the G88R variant (NM_024557.4:c.262G>A, NP_078833.3:p.G88R) into RIC3 (RIC3G88R).

RIC3WT and RIC3G88R cDNAs were subsequently cloned into the MCS of pEGFP-N1 (NovoPro Bioscience, Shanghai, China) to fuse the fluorescent eGFP tag to the C-terminus of RIC3WT (RIC3WT-eGFP) or RIC3G88R (RIC3G88R-eGFP) or pEGFP-C1 (NovoPro Bioscience, Shanghai, China) to fuse the eGFP tag to the N-terminus of the RIC3 protein (eGFP-RIC3WT and eGFP-RIC3G88R).

Western blots

HEK293T cells were seeded at 3.5×10^6 cells per 10 cm plate and transfected with 17.5 µg plasmid (eGFP-RIC3WT or eGFP-RIC3G88R). After 48 h, protein lysates were extracted and quantified using a BCA assay. Proteins were separated on a 10% SDS-PAGE gel for 30 min before transfer to a nitrocellulose membrane using a semi-dry protocol for high MW proteins. Membranes were blocked in 5% milk powder in 1×TBS Tween before detection with primary rabbit polyclonal antibodies for GFP (AbCam; ab290) and

secondary goat anti-rabbit IgG (Licor.com; IRDye 680RD) for RIC3 detection. A primary mouse monoclonal antibody for α -tubulin (Merck; T5168) with secondary anti-mouse IgG (Licor.com; IRDye 800CW) was used as a positive control. All antibodies were used at a 1 in 1000 dilution. Membranes were washed six times with 1 × TBS Tween and visualized on a Typhoon biomolecular imager (Cytiva) against a marker precision plus ladder (Biorad; 161-0374).

Confocal microscopy and acceptor photobleaching FRET

Acceptor photobleaching fluorescence resonance energy transfer (apFRET) [48, 49] was used to detect interactions between the tagged α 7 and RIC3 proteins using a Zeiss LSM880 confocal microscope 2 days after transfection.

eGFP was used as the FRET donor and mCherry as the FRET acceptor. pmCherry-eGFP (Addgene, plasmid#86639) was used as positive control, while mCherry-ER3 (Addgene, plasmid#55041) and LCK-GFP (Addgene, plasmid#61099) were used as negative controls for RIC3-eGFP and α7-mCherry, respectively. FRET between donor and acceptor was confirmed by bleaching of mCherry which lasted 5 s and monitoring the concomitant increase in eGFP fluorescence across five successive 0.47 s windows. mCherry was excited with 561 nm light and eGFP with 488 nm light. The mCherry and eGFP laser transmission was kept at 2% and 1.5%, respectively, during scanning to avoid photobleaching but mCherry was set at 100% during bleaching. HEK293 cells expressing either eGFP or mCherry alone were imaged with the apFRET settings to confirm that fluorophore crosstalk was minimized, and that the bleaching step did not reduce eGFP fluorescence. Five pre-bleach and five post-bleach scans of the eGFP and mCherry fluorescence were carried out at 0.47 s intervals in a constant sized region of interest (ROI) which was manually selected to represent an ER location with comparable levels of red and green fluorescence. Fluorescence intensity was monitored in the ROI and analyzed using Microsoft Excel. For data analysis, the eGFP fluorescence intensity was normalized onto a percentage scale as described previously [48, 49]. To calculate the FRET efficiency $E_{\rm F}$, the following equation was used, as described by Graumann et al. [49]:

$E_F = eGFPpost - eGFPpre$

where eGFPpost is the fluorescence intensity immediately after the photobleaching (scan 6) and eGFPpre is the average fluorescence intensity across all five scans before the photobleaching. Note that this calculation assumes 100% photobleaching of the acceptor [50]. All confocal work was performed at the Oxford Brookes Centre for Bioimaging. For each experimental and control sample, approximately 100 live cells (in DMEM) were imaged with a 63×oil immersion objective (Plan-Apochromat 63×/1.4 Oil DIC M27) at 37 °C and 5% CO₂. Each experiment was repeated three times. After excluding outliers (> ± 1.5(IQR)), the number of intensity measurements included in the FRET calculation for each condition were N=246 (α 7-mCherry+eGFP-RIC3WT), N=257 (α 7-mCherry+eGFP-RIC3G88R), N=233 (α 7-mCherry+LCK-GFP, negative control), N=239 (eGFP-RIC3WT+mCherry-ER3, negative control), N=231 (eGFP-RIC3G88R+mCherry-ER3, negative control), N=244 (pmCherry-ER3-eGFP, positive control).

¹²⁵I-α-Bungarotoxin binding

RIC3WT or mutant RIC3G88R cDNA, in combination with α 7 cDNA (at a ratio of 1:5 or 1:1), were transfected into HEK293 cells using polyethylenimine. Surface α 7 expression was determined 48 h after transfection by overlaying the cells in phosphate-buffered saline (PBS) containing 10 nM ¹²⁵I- α -bungarotoxin and 1 mg/mL bovine serum albumin for 60 min. Cells were washed four times with PBS and removed from the plate in 10 mM Tris–HCl (pH 7.4), 100 mM NaCl, 1 mM ethylenediaminetetraacetate, and 1% Triton X-100. ¹²⁵I- α -Bungarotoxin binding was determined by gamma counter.

Functional expression of nAChR in Xenopus oocytes

Electrophysiological experiments were carried out on oocytes nuclearly injected with either α 7 cDNA, RIC3WT, RIC3G88R, α 7 + RIC3WT or α 7 + RIC3G88R. We also tested the effects of wild-type and variant RIC3 on the functional expression of human α 4 β 2 nAChRs. For these experiments, oocytes were nuclearly injected with equal amounts of α 4 and β 2 cDNA. For both types of injections (α 7and α 4 β 2 nAChR subunit cDNAs), the total amount of cDNA injected was kept at 5 ng for nAChR subunit cDNA and 1 nG for RIC cDNAs. Oocytes were harvested from mature *Xenopus laevis* females and used for electrophysiological experiments 2 days after injection, as described previously [51].

Acetylcholine-induced currents in Xenopus oocytes expressing heterologously α 7 nAChR were recorded using an automated platform equipped with standard two electrode voltage-clamp configuration (HiClamp; Multi Channel Systems, Reutlignen, Germany). The electrodes were filled with 3 M KCl and the recordings were carried at a holding potential of – 60 mV throughout the experiment. All recordings were performed at 18 °C, and cells were perfused with a solution containing 82 mM NaCl, 2 mM KCl, 2 mM CaCl₂, 5 mM HEPES at pH 7.4. Data were filtered at 10 Hz, captured at 100 Hz, and analyzed using proprietary data acquisition and analysis software running under Matlab (Mathworks Inc., Natick, MA). Maximal functional expression was determined using 1 mM acetylcholine, a concentration that produces maximal current responses at oocytes expressing α 7 nAChRs [51]. The concentration–response curve for acetylcholine at $\alpha 7$ nAChR was also determined to establish whether the variant affected the function of a7 nAChR. For these experiments, we used a protocol of 7-8 concentrations of acetylcholine with a reference response (1 mM ACh, a maximal ACh concentration in wild-type human α 7 nAChR). Acetylcholine was applied for 10 s and the washing period between applications was 5 min to allow for full recovery from receptor desensitization [51]. The concentration-response data were fit with the Hill equation to estimate the acetylcholine potency (ACh EC₅₀), as previously described [51]. For $\alpha 4\beta 2$ nAChR assays, functional expression of $\alpha 4\beta 2$ nAChR in oocytes injected with $\alpha 4$ and $\beta 2$ cDNAs ± WT RIC3 or RIC3G88R cDNA was assessed by measuring the amplitude of current responses elicited by application of a maximal ACh (1 mM) to the impaled oocytes. For these assays, currents were recorded using an oocyte clamp OC-725Camplifier (Warner Instruments). For all receptor subtypes assayed and examined, the current responses to ACh were recorded 2 days after injection and all experimental conditions (RIC3WT or RIC3G88R) were done on the same day.


Image processing and statistical analysis

Images were analyzed within Fiji [52] to assess co-localization of proteins. Images were imported as raw. czi files and a single timepoint was extracted for the red and green channels. All images were subject to background subtraction using sliding paraboloid method with a rolling ball of radius 50 pixels. Co-localization analyses were performed on a region of interest that included the whole cell using a Coloc2 plugin (https://imagej.net/plugins/coloc-2). 2D intensity histograms for the representative images shown in Figs. 2 and 3 are provided as Supplementary data. Co-localization is reported as Pearson correlation coefficients (PCC) throughout.

Unadjusted representative images were exported as montages of raw files in which red was replaced with magenta. Brightness and contrast were adjusted for all channels simultaneously in PowerPoint.

Data are expressed as means \pm SEM from 100 experiments carried out using 12–14 batches of transfected cell batches or ten *Xenopus* donors. Data are reported as mean \pm SEM. To compare significant differences (at *p* < 0.05) between more than two groups of data meeting assumptions of normality and equal variance, a one-way ANOVA was performed followed by a Tukey test for all pair-wise comparisons.

Fig. 2 Cellular localization of RIC3WT and RIC3G88R. A: Western blot of transfected cells showed the presence of an eGFP-RIC3 protein at the expected 67KDa size (UnTuntransfected HEK293 cells). Two biological replicates were performed (R1 and R2). No observable differences were present between wild-type (WT) and variant (G88R) cell-lines. B and C: N-terminal fusion of eGFP on wild-type (eGFP-RIC3WT) and G88R (eGFP-RIC3G88R). D and E: C-terminal fusion of eGFP on wild-type (RIC3WT-eGFP) and G88R (RIC3G88R-eGFP) Formation of RIC3 bright oval structures was observed in the ER. RIC3 demonstrated a strong overlap with the ER marker (mCherry-ER3) in both the wild-type (WT) and variant (G88R) forms and for both N-terminal and C-terminal fusions. The average Pearson correlation coefficient (PCC) across five representative images for eGFP-RIC3WT+mCherry-ER3 (Panel B) was 0.73 (SD = 0.12), for eGFP-RIC3G88R+mCherry-ER3 (Panel C) was 0.67 (SD=0.08), for RIC3WTeGFP+mCherry-ER3 (Panel **D**) was 0.61 (SD = 0.14)and for RIC3G88ReGFP+mCherry-ER3 (Panel **E**) was 0.78 (SD = 0.11). Size $bars = 10 \mu m$. Raw Western blot images are provided in supplementary data



Results

RIC3G88R localization

Previous studies consistently report that RIC3 localizes to the ER, where it binds unassembled α 7 subunits promoting receptor assembly [17, 21, 53]. Therefore, we first sought to assess whether the G88R variant affected RIC3 cellular localization. Both RIC3WT and RIC3G88R were fused to eGFP at the N-(eGFP-RIC3WT and eGFP-RIC3G88R) or C-(RIC3WT-eGFP and RIC3G88R-eGFP) terminus and transiently expressed in HEK293 cells.

All four RIC3 clones co-localized with mCherry-ER3, an ER-resident protein marker (Fig. 2b–e, see Figure legends for Pearson Correlation Coefficients) confirming an ER localization for RIC3 and indicating that the G88R variant does not overtly alter cellular localization (Fig. 2b–e). In addition to the ER localization, both RIC3WT-eGFP and RIC3G88R-eGFP also resulted in bright ring structures (Fig. 2d and e). Similar bodies were observed by Wang




Fig.3 Interaction between α 7 and eGFP-RIC3WT or eGFP-RIC3G88R measured by apFRET. **A**: Representative confocal images of the proteins of interest (α 7 and RIC3WT (Panel i), α 7 and RIC3G88R (Panel ii)). eGFP was used as the FRET donor and mCherry as the FRET acceptor. pmCherry-eGFP (Addgene, plasmid#86639) was used as positive control (Panel iii), while LCK-GFP (Addgene, plasmid#61099) and α 7-mCherry were used as negative controls (Panel iv). **B**: Normalized donor and acceptor fluorescence intensity post-acceptor photobleaching. Each interval is 0.47 s. Photobleaching occurred across 5 s at time interval 5. Error bars represent SD across all measurements within each of the experimental conditions. See methods for details of normalization and N. C: FRET efficiencies measured for α 7 and eGFP-RIC3WT or eGFP-RIC3G88R and controls, as described in methods. Boxes

represent interquartile range of FRET intensity (see Methods for *N*), with lines at the median and crosses denoting mean of distribution. RIC3 demonstrated a strong overlap with α 7 in both the wild-type (WT) and variant (G88R) forms. The average Pearson correlation coefficient (PCC) across five representative images for eGFP-RIC3WT + α 7-mCherry (Panel A(i)) was 0.70 (SD=0.08) and for eGFP-RIC3G88R+ α 7-mCherry (Panel A(ii)), the average PCC was 0.72 (SD=0.04). The positive controls (pmCherry-eGFP) also showed a strong co-localization (Panel A(iii))—PCC across five representative images was 0.82 (SD=0.09), while the negative controls (LCK-GFP+mCherry) had minimal overlap (Panel A(iv))—PCC across five representative images was 0.26 (SD=0.11). Size bars=10 µm

et al. using mouse *Ric3*, who suggested that this pattern may arise from over-expression leading to homotypic interactions between *Ric3* [17]. In addition, it was observed that both RIC3WT-eGFP and RIC3G88R-eGFP transfections led to a distorted ER structure (Fig. 2d and e), further indicating disruption of the secretory pathway. eGFP-RIC3WT (Fig. 2b) and eGFP-RIC3G88R (Fig. 2c) were, therefore, used for the remainder of experiments in this paper. Western

blots confirmed that the full-length eGFP-RIC3 protein was present at 67KDa as expected (Fig. 2a).

Interaction between α7 and RIC3

To obtain direct evidence whether the RIC3 variant affected interaction with α 7, acceptor photobleaching fluorescence resonance energy transfer (apFRET) was employed (Fig. 3). This method is based on the fact that when energy transfer occurs, the fluorescence emission by the donor fluorochrome is quenched because of the direct transfer of excitation energy to the acceptor fluorochrome. If the acceptor fluorochrome is fully bleached by a laser, FRET is dampened and the donor signal is de-quenched, thus resulting in an enhanced fluorescence emission by the donor fluorophore [21, 54]

α7 was labeled with mCherry and was observed to co-localize with eGFP-RIC3 (Fig. 3, see Figure legend for Pearson correlation coefficients). FRET efficiency between α7 and eGFP-RIC3G88R, E_F =10.73% ±7.06, N=100, was significantly higher (p < 0.05; ANOVA plus Tukey test) than that observed for eGFP-RIC3WT (E_F =7.24% ±5.97, N=100) (Fig. 3). Furthermore, the fluorescent signal emitted by the donor (eGFP) fluorochrome as a result of dequenching was 1.5-fold higher in cells carrying the variant compared to wild type (N=30; p < 0.05; ANOVA plus Tukey test) (Fig. 3b and c) and this change persisted over the duration of the experiment (Fig. 3b). These results collectively suggest that the G88R SNP enhances interactions between RIC3 and α7 nAChR subunits.

Cell surface expression

To evaluate the effect of the enhanced interaction between α 7 and RICG88R on cell surface expression, we performed ¹²⁵I-α-bungarotoxin binding on intact HEK293 cells co-transfected with mCherry a7 and eGFP-RIC3WT or eGFP-RIC3G88R. The cDNAs were transfected at either 1:1 or 5:1 a7:RIC3 ratios. a-Bungarotoxin is a neurotoxin that binds competitively to the agonist binding site of α 7 nAChR subunits. The agonist binding site in nAChR is located between two adjacent subunits; hence, 125 I- α bungarotoxin binding to cells transfected with α7 cDNA can be used to probe receptor assembly. Cells transfected with α 7 nAChR cDNA did not bind ¹²⁵I- α -bungarotoxin (data not shown). In contrast, in the presence of RIC3, robust specific 125 I- α -bungarotoxin binding was observed (Fig. 4). As shown in Fig. 4a, regardless of the transfection ratio, RIC3G88R significantly decreased the binding of 125 I- α bungarotoxin (N = 6; p < 0.05; ANOVA) by almost 50%, suggesting that enhanced RIC3-a7 interactions decrease cell surface expression of α 7 nAChR. The reduction of ¹²⁵I- α bungarotoxin binding observed with transfection ratios of 1:1 or 5:1 was not statistically different to each other, in accordance with the findings of Dau et al., who reported that RIC3 significantly enhanced cell surface α -bungarotoxin binding above control levels at both 1:1 and 5:1 α 7:RIC3 ratios [21].

Next, we examined whether the reduced cell surface expression of α 7 nAChR affected α 7 function. To examine function, α 7 was expressed in the absence or presence of untagged RIC3WT or RIC3G88R in Xenopus oocytes, a well-established expression system ideally suited for electrophysiological recordings of recombinant ion channels. The nucleus of oocytes was injected with α7:RIC3 cDNA at a ratio of 1:1 or 5:1, and the amplitude of currents generated by 1 mM acetylcholine was recorded. At this concentration, acetylcholine stimulates maximal current responses in a7 nAChR, which are indicative of the level of functional receptors present. As shown in Fig. 4b, functional expression of α 7 nAChR in the absence or presence of RIC3 does not impact the potency of Ach, as previously reported [55]. Regardless of the α 7:RIC3 cDNA ratio, in the presence of RIC3WT, the expression of functional α 7 nAChR increased by approximately twofold (Fig. 4c, N=15, p < 0.001), further supporting the ability of this chaperone to promote surface expression in Xenopus oocytes. Consistent with the findings of the binding studies, the levels of functional α 7 nAChR decreased by about 1.5-fold in the presence of RIC3G88R (Fig. 4c, p < 0.05). Tagged α 7 and RIC3WT or RIC3G88R produced the same pattern as the non-tagged constructs (data not shown). In addition, we also examined the effect of RIC3WT or RIC3G88R on the functional expression of human $\alpha 4\beta 2$ nAChR. As shown in Fig. 4c, under our experimental conditions (5 ng of $\alpha 4 + \beta 2$ cDNA mixture ± 1 ng RIC cDNA), both RIC3WT and RIC3G88R increased the expression of $\alpha 4\beta 2$ nAChR similarly; however, none of these effects were statistically significant compared to control ($\alpha 4\beta 2$) (N = 10 recordings from two oocyte donors). Previous studies have shown that the effect of RIC3 on functional expression of α4β2 nAChR is not consistent, suggesting that, in oocytes, the effects may depend on other elements expressed in oocytes [18, 19, 21]. Thus, RIC3G88R appears to selectively impact the functional expression of α 7 nAChR.

Discussion

While several general protein chaperones modulate the maturation and trafficking of nAChRs [56], RIC3 is relatively specific in its chaperone activity exerting significant effect upon the folding and assembly of α 7 receptors [20]. Interestingly, a rare genetic variant of RIC3 (NP_078833.3:p.G88R) was potentially implicated in a unique ability to speak backwards that is associated with




Fig.4 RIC3G88R variant decreases cell surface expression of α 7 nAChR. **A** Cell surface expression of α 7 nAChRs was assayed by ¹²⁵I- α -bungarotoxin binding to intact HEK293 cells transfected with mCherry α 7 and either RIC3WT or RIC3G88R at 5:1 or 1:1 cDNA

ratio. **B**: The potency with which acetylcholine activates responses in α 7 nAChRs is not affected by RIC3WT or the variant RIC3G88R (*N*=5). **C**: Histograms of the maximal currents activated by 1 mM Ach in α 7 (*N*=15) and α 4 β 2 (*N*=10)

higher working memory capacity [38]. This variant was one of three novel coding changes that co-segregated with the trait in the discovery family but the authors particularly highlighted the *RIC3* polymorphism, hypothesizing that this may exert a function upon cholinergic systems [38]. In this investigation, we, therefore, sought to establish the functional level of effects mediated by this coding change in *RIC3*. We find that RIC3G88R significantly increased interaction with α 7 compared to the wild-type RIC3. Subsequent ¹²⁵I- α -bungarotoxin binding to α 7 and functional assays showed that RIC3G88R decreased cell surface binding and functional expression, suggesting that enhanced RIC3- α 7 interactions in the ER reduce cell surface and functional expression of α 7 nAChR. This finding indicates that the polymorphism RIC3G88R modifies RIC3- α 7 interactions and that this change substantially affects α 7 nAChR surface expression. The exact relationship between this functional pathway and backwards speech is still to be elucidated. Many questions remain regarding the way in which RIC3 moderates receptor assembly and function and whether these effects are specific to certain receptor types. Understanding these mechanisms will be critical to the functional characterization of this variant, which may act at many different levels.

Our investigations show that eGFP-RIC3WT produced a significantly higher FRET signal/efficiency compared to the negative controls. A previous study also used FRET to demonstrate increased assembly and cell-surfacing trafficking of α 7 in the presence of RIC3 [21]. However, this investigation used a different FRET method (sensitized emission) and measured interaction between α 7 subunits [21]. Others have shown co-immunoprecipitation of RIC3 and $\alpha 7$ [16]. Our findings add to this baseline to further suggest a direct interaction between RIC3 and α 7 within the ER. Interestingly, the FRET signal produced by eGFP-RIC3G88R was almost 1.5-fold greater than that seen with eGFP-RIC3WT. This strongly indicates that there is a direct interaction between RIC3 and α 7 and that the p.G88R polymorphism implicated in backwards speech strengthens this interaction, resulting in a reduced surface expression, as shown by 125 I- α -bungarotoxin binding and the decrease in the amplitude of the maximal currents elicited by Ach in oocytes expressing heterologously a7 nAChR and RIC3G88R. Although the role of RIC3 in α 7-signaling dysfunction has not been explored, α 7 nAChR expression is reduced in the brain of schizophrenic patients [5, 57] and the levels of RIC3 mRNA in the brains of schizophrenia patients, postmortem, are greater than in typical brains [26]. Chaperones of nAChR have been previously linked to cholinergic dysfunction. A variant of rapsyn, a muscle nAChR chaperone that concentrates and anchors muscle nAChR in the postsynaptic membrane of the neuromuscular junction, causes congenital myasthenic syndrome by altering interactions with the receptor muscle specific tyrosine kinase (MuSK) [58].

Variant G88R occurs within a poly-glycine stretch found within the proline-rich linker that joins the hydrophobic domains of RIC3. Deletion of the entire proline-rich linker in human RIC3 [25] attenuates α 7 surface expression, indicating the importance of this region for the chaperone activity of RIC3, although specific singular residues are unlikely to account for this effect. The poly-glycine segment is not thought to adopt a specific folding pattern but we propose that the G-R change creates a positively charge that may alter the configuration of the proline region, thus affecting chaperone activity of RIC3.

We found that N-terminal fusion of wild-type RIC3 to eGFP (eGFP-RIC3) does not impair the expression of RIC3 in the ER or the chaperone activity of this protein. These findings are in accord with previous studies of human RIC3 that have used N-terminal fusion RIC3 constructs to examine the chaperone activity of this protein [21, 53]. The observation of FRET activity between eGFP-RIC3 and α 7 directly indicates that RIC3 is a type II transmembrane protein, since the N-terminus of RIC3 must have a cytoplasmic location to allow this interaction (Fig. 1a). This supposition opposes the findings of Wang et al. who working with a C-terminal tagged mouse RIC3 construct suggested that the mouse Ric3 N-terminus is cleaved during translation [17].

In contrast, the expression of the C-terminal fusion, RIC3-eGFP, led to rings of bright fluorescence and a disordered ER, reminiscent of ER-phagy [59]. These observations suggest that tagging of the C-terminus disrupts RIC3 function leading to misfolded polypeptides within the ER and subsequent removal of damaged ER sections. If the misfolded proteins are α 7, then this implicates a direct role for RIC3 in α 7 folding as suggested by [17]. Given the disordered nature of RIC3, the localization of the exact interaction domain has proven to be challenging [41].

In summary, our investigations shed light upon the interaction between RIC3 and α 7 in the assembly and trafficking of this important neuronal receptor. Specifically, we demonstrate that the RIC3G88R variant has a functional effect by increasing RIC3 interaction with α 7 subunits in the ER and that this ultimately leads to a reduction in the cell surface and functional expression of α 7 nAChR. How may a decrease in α 7 receptor expression influence the ability to speak backwards? Backward speech relies on a strong working memory capacity [38] and memory is influenced by α 7 nAChR signaling [60]. The role of α 7 nAChR in cognition is linked to its modulation of glutamatergic and GABAergic signaling but the mechanisms driving this effect are not well-understood. This is largely due to the complexity of α 7-signaling, which is affected by diverse elements including cell type, location, and complex relationship between timing of activation relative to associated glutamatergic and GABAergic pathways involved in cognition and memory (for a review, see [61]). Thus, decreased functional expression of a7 nAChR could potentially upset the balance between the modulation of excitatory/inhibitory pathways. Alternatively, decreased expression of α7 nAChR may alter neuronal development, when the foundations for the cognitive and language functions of the brain are first laid. ¹²⁵I-\alpha-Bungarotoxin binding sites are present in the human fetal brain [62], and the α 7 nAChR has been implicated in neuronal migration [63] and early post-natal synapse formation [64, 65]. Thus, RIC3 can potentially affect the ability to speak backwardly by affecting the establishment of the signaling circuitries involved in speech. Further investigations will be required to link this functional finding to the reported language phenotype, providing important evidence about the function of both RIC3 and a7 nAChR in neurodevelopment.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00018-024-05149-8.

Acknowledgements All confocal work was performed at the Oxford Brookes Centre for Bioimaging. We thank John Runions and Verena Kriechbaumer for their valuable advice. We thank Raad Nashmi (University of Victoria, Canada) for his advice on the design of the fluorescence constructs used in this study.

Author contribution DN, IB, SP, HM, ER, SM, DB designed the experiments. AP, ER, JP carried out the confocal studies and analyzed the data. SP, EE, JSS, and JC performed the Western blot assays. IB designed and carried out functional assays in *Xenopus* oocytes. SM

carried out α -bungarotoxin binding assays. IB, DM, DB, RW, YD, DN, HM provided supervision. AP, IB, DN wrote manuscript and prepared the figures. All authors contributed to and agreed manuscript content.

Funding This work was supported by a project grant from the Leverhulme Trust Foundation (RPG-207-381). JP was funded by a Nigel Groome Brookes University studentship. DB, SM, and RW were supported by MRC grant MR/S007180/M. YD was supported by MRC Grant MR/M006824/1.

Data availability The datasets generated during and/or analyzed during the current study are available in the Oxford Brookes RADAR repository [https://doi.org/10.24384/mp84-n694].

Declarations

Conflict of interest The authors have no relevant financial or non-financial interests to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD (2010) Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 16:323–343. https://doi.org/10. 2174/138161210790170094
- Wallace TL, Porter RH (2011) Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol 82:891–903. https://doi.org/10.1016/j.bcp.2011.06.034
- Freedman R (2014) alpha7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annu Rev Med 65:245–261. https://doi.org/10.1146/annur ev-med-092112-142937
- 4. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 94:587–592. https://doi.org/10.1073/pnas.94.2.587
- Freedman R, Hall M, Adler LE, Leonard S (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38:22–33. https://doi.org/10.1016/0006-3223(94)00252-X
- 6. Qi XL, Nordberg A, Xiu J, Guan ZZ (2007) The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of

Alzheimer's disease. Neurochem Int 51:377–383. https://doi.org/ 10.1016/j.neuint.2007.04.002

- Ren JM, Zhang SL, Wang XL, Guan ZZ, Qi XL (2020) Expression levels of the alpha7 nicotinic acetylcholine receptor in the brains of patients with Alzheimer's disease and their effect on synaptic proteins in SH-SY5Y cells. Mol Med Rep 22:2063–2075. https:// doi.org/10.3892/mmr.2020.11253
- Weng PH, Chen JH, Chen TF, Sun Y, Wen LL, Yip PK, Chu YM, Chen YC (2016) CHRNA7 polymorphisms and dementia risk: interactions with apolipoprotein epsilon4 and cigarette smoking. Sci Rep 6:27231. https://doi.org/10.1038/srep27231
- Weng PH, Chen JH, Chen TF, Sun Y, Wen LL, Yip PK, Chu YM, Chen YC (2013) CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease. PLoS ONE 8:e84059. https://doi.org/10.1371/journal.pone.0084059
- Russo P, Kisialiou A, Moroni R, Prinzi G, Fini M (2017) Effect of genetic polymorphisms (SNPs) in CHRNA7 gene on response to acetylcholinesterase inhibitors (AChEI) in patients with Alzheimer's disease. Curr Drug Targets 18:1179–1190. https:// doi.org/10.2174/1389450116666151001111826
- Stephens SH, Logel J, Barton A, Franks A, Schultz J, Short M, Dickenson J, James B, Fingerlin TE, Wagner B, Hodgkinson C, Graw S, Ross RG, Freedman R, Leonard S (2009) Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. Schizophr Res 109:102–112. https://doi.org/10. 1016/j.schres.2008.12.017
- Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, Zhang J, Lucero L, Wang M, Sierks M, Hu G, Chang Y, Lukas RJ, Wu J (2009) A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 29:918–929. https://doi.org/10.1523/JNEUR OSCI.3952-08.2009
- Kabbani N, Nichols RA (2018) Beyond the channel: metabotropic signaling by nicotinic receptors. Trends Pharmacol Sci 39:354– 366. https://doi.org/10.1016/j.tips.2018.01.002
- Green WN, Millar NS (1995) Ion-channel assembly. Trends Neurosci 18:280–287. https://doi.org/10.1016/0166-2236(95) 80009-Q
- Halevi S, McKay J, Palfreyman M, Yassin L, Eshel M, Jorgensen E, Treinin M (2002) The *C. elegans* ric-3 gene is required for maturation of nicotinic acetylcholine receptors. EMBO J 21:1012–1020. https://doi.org/10.1093/emboj/21.5.1012
- Lansdell SJ, Gee VJ, Harkness PC, Doward AI, Baker ER, Gibb AJ, Millar NS (2005) RIC-3 enhances functional expression of multiple nicotinic acetylcholine receptor subtypes in mammalian cells. Mol Pharmacol 68:1431–1438. https://doi.org/10.1124/mol. 105.017459
- Wang Y, Yao Y, Tang XQ, Wang ZZ (2009) Mouse RIC-3, an endoplasmic reticulum chaperone, promotes assembly of the alpha7 acetylcholine receptor through a cytoplasmic coiled-coil domain. J Neurosci 29:12625–12635. https://doi.org/10.1523/ JNEUROSCI.1776-09.2009
- Lansdell SJ, Collins T, Yabe A, Gee VJ, Gibb AJ, Millar NS (2008) Host-cell specific effects of the nicotinic acetylcholine receptor chaperone RIC-3 revealed by a comparison of human and Drosophila RIC-3 homologues. J Neurochem 105:1573–1581. https://doi.org/10.1111/j.1471-4159.2008.05235.x
- Halevi S, Yassin L, Eshel M, Sala F, Sala S, Criado M, Treinin M (2003) Conservation within the RIC-3 gene family. Effectors of mammalian nicotinic acetylcholine receptor expression. J Biol Chem 278:34411–34417. https://doi.org/10.1074/jbc.M3001 70200
- Williams ME, Burton B, Urrutia A, Shcherbatko A, Chavez-Noriega LE, Cohen CJ, Aiyar J (2005) Ric-3 promotes functional expression of the nicotinic acetylcholine receptor

alpha7 subunit in mammalian cells. J Biol Chem 280:1257–1263. https://doi.org/10.1074/jbc.M410039200

- Dau A, Komal P, Truong M, Morris G, Evans G, Nashmi R (2013) RIC-3 differentially modulates alpha4beta2 and alpha7 nicotinic receptor assembly, expression, and nicotine-induced receptor upregulation. BMC Neurosci 14:47. https://doi.org/10. 1186/1471-2202-14-47
- Ben-David Y, Mizrachi T, Kagan S, Krisher T, Cohen E, Brenner T, Treinin M (2016) RIC-3 expression and splicing regulate nAChR functional expression. Mol Brain 9:47. https:// doi.org/10.1186/s13041-016-0231-5
- 23. Deshpande A, Vinayakamoorthy RM, Garg BK, Thummapudi JP, Oza G, Adhikari K, Agarwal A, Dalvi P, Iyer S, Thulasi Raman S, Ramesh V, Rameshbabu A, Rezvaya A, Sukumaran S, Swaminathan S, Tilak B, Wang Z, Tran PV, Loring RH (2020) Why does knocking out NACHO, but not RIC3, completely block expression of alpha7 Nicotinic receptors in mouse brain? Biomolecules. https://doi.org/10.3390/biom10030470
- Yokoyama JS, Evans DS, Coppola G, Kramer JH, Tranah GJ, Yaffe K (2014) Genetic modifiers of cognitive maintenance among older adults. Hum Brain Mapp 35:4556–4565. https:// doi.org/10.1002/hbm.22494
- Castelan F, Castillo M, Mulet J, Sala S, Sala F, Dominguez Del Toro E, Criado M (2008) Molecular characterization and localization of the RIC-3 protein, an effector of nicotinic acetylcholine receptor expression. J Neurochem 105:617–627. https://doi.org/10.1111/j.1471-4159.2007.05169.x
- Severance EG, Yolken RH (2007) Lack of RIC-3 congruence with beta2 subunit-containing nicotinic acetylcholine receptors in bipolar disorder. Neuroscience 148:454–460. https://doi.org/ 10.1016/j.neuroscience.2007.06.008
- Simpson NH, Ceroni F, Reader RH, Covill LE, Knight JC, Consortium SLI, Hennessy ER, Bolton PF, Conti-Ramsden G, O'Hare A, Baird G, Fisher SE, Newbury DF (2015) Genomewide analysis identifies a role for common copy number variants in specific language impairment. Eur J Hum Genet 23:1370– 1377. https://doi.org/10.1038/ejhg.2014.296
- Pettigrew KA, Reeves E, Leavett R, Hayiou-Thomas ME, Sharma A, Simpson NH, Martinelli A, Thompson P, Hulme C, Snowling MJ, Newbury DF, Paracchini S (2015) Copy number variation screen identifies a rare de novo deletion at chromosome 15q13.1–13.3 in a child with language impairment. PLoS ONE 10:e0134997. https://doi.org/10.1371/journal.pone. 0134997
- Gialluisi A, Visconti A, Willcutt EG, Smith SD, Pennington BF, Falchi M, DeFries JC, Olson RK, Francks C, Fisher SE (2016) Investigating the effects of copy number variants on reading and language performance. J Neurodev Disord 8:17. https://doi.org/ 10.1186/s11689-016-9147-8
- Deutsch SI, Burket JA, Benson AD, Urbano MR (2016) The 15q13.3 deletion syndrome: deficient alpha(7)-containing nicotinic acetylcholine receptor-mediated neurotransmission in the pathogenesis of neurodevelopmental disorders. Prog Neuropsychopharmacol Biol Psychiatry 64:109–117. https://doi. org/10.1016/j.pnpbp.2015.08.001
- DiStefano C, Gulsrud A, Huberty S, Kasari C, Cook E, Reiter LT, Thibert R, Jeste SS (2016) Identification of a distinct developmental and behavioral profile in children with Dup15q syndrome. J Neurodev Disord 8:19. https://doi.org/10.1186/ s11689-016-9152-y
- 32. Shinawi M, Schaaf CP, Bhatt SS, Xia Z, Patel A, Cheung SW, Lanpher B, Nagl S, Herding HS, Nevinny-Stickel C, Immken LL, Patel GS, German JR, Beaudet AL, Stankiewicz P (2009) A small recurrent deletion within 15q13.3 is associated with a range of neurodevelopmental phenotypes. Nat Genet 41:1269–1271. https://doi.org/10.1038/ng.481

- 33. Gillentine MA, Berry LN, Goin-Kochel RP, Ali MA, Ge J, Guffey D, Rosenfeld JA, Hannig V, Bader P, Proud M, Shinawi M, Graham BH, Lin A, Lalani SR, Reynolds J, Chen M, Grebe T, Minard CG, Stankiewicz P, Beaudet AL, Schaaf CP (2017) The cognitive and behavioral phenotypes of individuals with CHRNA7 duplications. J Autism Dev Disord 47:549–562. https://doi.org/10. 1007/s10803-016-2961-8
- Gillentine MA, Schaaf CP (2015) The human clinical phenotypes of altered CHRNA7 copy number. Biochem Pharmacol 97:352– 362. https://doi.org/10.1016/j.bcp.2015.06.012
- Rodriguez-Ferrera S, McCarthy RA, McKenna PJ (2001) Language in schizophrenia and its relationship to formal thought disorder. Psychol Med 31:197–205. https://doi.org/10.1017/s0033 29170100321x
- 36. de Boer JN, Brederoo SG, Voppel AE, Sommer IEC (2020) Anomalies in language as a biomarker for schizophrenia. Curr Opin Psychiatry 33:212–218. https://doi.org/10.1097/YCO.00000 00000000595
- 37. Dwyer KR, Andrea AM, Savage CLG, Orth RD, Shan L, Strauss GP, Adams HA, Kelly DL, Weiner E, Gold JM, McMahon RP, Carpenter WT, Buchanan RW, Blanchard JJ (2020) A randomized clinical trial of oxytocin or galantamine in schizophrenia: assessing the impact on behavioral, lexical, and self-report indicators of social affiliation. Schizophr Bull Open 1:001. https:// doi.org/10.1093/schizbullopen/sgaa001
- 38. Prekovic S, Đurđević DF, Csifcsák G, Šveljo O, Stojković O, Janković M, Koprivšek K, Covill LE, Lučić M, Van den Broeck T, Helsen C, Ceroni F, Claessens F, Newbury DF (2016) Multidisciplinary investigation links backward-speech trait and working memory through genetic mutation. Sci Rep 6:20369. https://doi.org/10.1038/srep20369
- Cheng A, Bollan KA, Greenwood SM, Irving AJ, Connolly CN (2007) Differential subcellular localization of RIC-3 isoforms and their role in determining 5-HT3 receptor composition. J Biol Chem 282:26158–26166. https://doi.org/10.1074/jbc.M7038 99200
- Castillo M, Mulet J, Gutierrez LM, Ortiz JA, Castelan F, Gerber S, Sala S, Sala F, Criado M (2005) Dual role of the RIC-3 protein in trafficking of serotonin and nicotinic acetylcholine receptors. J Biol Chem 280:27062–27068. https://doi.org/10.1074/jbc.M5037 46200
- Loring RH (2022) Speculation on how RIC-3 and other chaperones facilitate alpha7 nicotinic receptor folding and assembly. Molecules 27:4527. https://doi.org/10.3390/molecules2 7144527
- 42. Cohen Ben-Ami H, Biala Y, Farah H, Elishevitz E, Battat E, Treinin M (2009) Receptor and subunit specific interactions of RIC-3 with nicotinic acetylcholine receptors. Biochemistry 48:12329–12336. https://doi.org/10.1021/bi901234a
- Ben-Ami HC, Yassin L, Farah H, Michaeli A, Eshel M, Treinin M (2005) RIC-3 affects properties and quantity of nicotinic acetylcholine receptors via a mechanism that does not require the coiled-coil domains. J Biol Chem 280:28053–28060. https://doi. org/10.1074/jbc.M504369200
- 44. Kweon HJ, Gu S, Witham E, Dhara M, Yu H, Mandon ED, Jawhari A, Bredt DS (2020) NACHO engages N-glycosylation ER chaperone pathways for alpha7 nicotinic receptor assembly. Cell Rep 32:108025. https://doi.org/10.1016/j.celrep.2020.108025
- 45. Murray TA, Bertrand D, Papke RL, George AA, Pantoja R, Srinivasan R, Liu Q, Wu J, Whiteaker P, Lester HA, Lukas RJ (2012) alpha7beta2 nicotinic acetylcholine receptors assemble, function, and are activated primarily via their alpha7-alpha7 interfaces. Mol Pharmacol 81:175–188. https://doi.org/10.1124/ mol.111.074088
- 46. Jones AK, Buckingham SD, Sattelle DB (2010) Proteins interacting with nicotinic acetylcholine receptors: expanding

functional and therapeutic horizons. Trends Pharmacol Sci 31:455–462. https://doi.org/10.1016/j.tips.2010.07.001

- Rudell JC, Borges LS, Yarov-Yarovoy V, Ferns M (2020) The MX-helix of muscle nAChR subunits regulates receptor assembly and surface trafficking. Front Mol Neurosci 13:48. https://doi.org/ 10.3389/fnmol.2020.00048
- Karpova TS, Baumann CT, He L, Wu X, Grammer A, Lipsky P, Hager GL, McNally JG (2003) Fluorescence resonance energy transfer from cyan to yellow fluorescent protein detected by acceptor photobleaching using confocal microscopy and a single laser. J Microsc 209:56–70. https://doi.org/10.1046/j.1365-2818. 2003.01100.x
- Graumann K, Irons SL, Runions J, Evans DE (2007) Retention and mobility of the mammalian lamin B receptor in the plant nuclear envelope. Biol Cell 99:553–562. https://doi.org/10.1042/ bc20070033
- Nashmi R, Dickinson ME, McKinney S, Jareb M, Labarca C, Fraser SE, Lester HA (2003) Assembly of alpha4beta2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking, and nicotineinduced upregulation in clonal mammalian cells and in cultured midbrain neurons. J Neurosci 23:11554–11567. https://doi.org/ 10.1523/JNEUROSCI.23-37-11554.2003
- 51. Minguez-Vinas T, Nielsen BE, Shoemark DK, Gotti C, Sessions RB, Mulholland AJ, Bouzat C, Wonnacott S, Gallagher T, Bermudez I, Oliveira AS (2021) A conserved arginine with nonconserved function is a key determinant of agonist selectivity in alpha7 nicotinic ACh receptors. Br J Pharmacol 178:1651–1668. https://doi.org/10.1111/bph.15389
- 52. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682. https://doi.org/10.1038/nmeth.2019
- Alexander JK, Sagher D, Krivoshein AV, Criado M, Jefford G, Green WN (2010) Ric-3 promotes alpha7 nicotinic receptor assembly and trafficking through the ER subcompartment of dendrites. J Neurosci 30:10112–10126. https://doi.org/10.1523/ JNEUROSCI.6344-09.2010
- Jares-Erijman EA, Jovin TM (2003) FRET imaging. Nat Biotechnol 21:1387–1395. https://doi.org/10.1038/nbt896
- Cooper ST, Millar NS (1997) Host cell-specific folding and assembly of the neuronal nicotinic acetylcholine receptor alpha7 subunit. J Neurochem 68:2140–2151. https://doi.org/10.1046/j. 1471-4159.1997.68052140.x

- Colombo SF, Mazzo F, Pistillo F, Gotti C (2013) Biogenesis, trafficking and up-regulation of nicotinic ACh receptors. Biochem Pharmacol 86:1063–1073. https://doi.org/10.1016/j.bcp.2013.06. 023
- 57. Freedman R, Adams CE, Leonard S (2000) The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanat 20:299–306. https://doi.org/10.1016/s0891-0618(00)00109-5
- Engel AG, Shen XM, Selcen D, Sine SM (2008) Further observations in congenital myasthenic syndromes. Ann N Y Acad Sci 1132:104–113. https://doi.org/10.1196/annals.1405.039
- Reggiori F, Molinari M (2022) ER-phagy: mechanisms, regulation, and diseases connected to the lysosomal clearance of the endoplasmic reticulum. Physiol Rev 102:1393–1448. https:// doi.org/10.1152/physrev.00038.2021
- Levin ED (2012) alpha7-Nicotinic receptors and cognition. Curr Drug Targets 13:602–606. https://doi.org/10.2174/1389450128 00398937
- Letsinger AC, Gu Z, Yakel JL (2022) alpha7 nicotinic acetylcholine receptors in the hippocampal circuit: taming complexity. Trends Neurosci 45:145–157. https://doi.org/10. 1016/j.tins.2021.11.006
- Falk L, Nordberg A, Seiger A, Kjaeldgaard A, Hellstrom-Lindahl E (2002) The alpha7 nicotinic receptors in human fetal brain and spinal cord. J Neurochem 80:457–465. https://doi.org/10.1046/j. 0022-3042.2001.00714.x
- Quik M, Chan J, Patrick J (1994) alpha-Bungarotoxin blocks the nicotinic receptor mediated increase in cell number in a neuroendocrine cell line. Brain Res 655:161–167. https://doi.org/ 10.1016/0006-8993(94)91610-1
- 64. Bina KG, Guzman P, Broide RS, Leslie FM, Smith MA, O'Dowd DK (1995) Localization of alpha 7 nicotinic receptor subunit mRNA and alpha-bungarotoxin binding sites in developing mouse somatosensory thalamocortical system. J Comp Neurol 363:321–332. https://doi.org/10.1002/cne.903630212
- Broide RS, Leslie FM (1999) The alpha7 nicotinic acetylcholine receptor in neuronal plasticity. Mol Neurobiol 20:1–16. https:// doi.org/10.1007/BF02741361

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.